Literature DB >> 25740106

The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features.

Marion Eveillard1, Jacques Delaunay2, Steven Richebourg3, Laurence Lodé4, Richard Garand4, Soraya Wuillème4, François Duhoux5, Hélène Antoine-Poirel5, Catherine Godon4, Marie C Béné4.   

Abstract

Entities:  

Keywords:  EVI1; PRDM16; acute myeloblastic leukemia

Mesh：

Substances：

Year:  2015        PMID： 25740106      PMCID： PMC4349292          DOI： 10.3324/haematol.2014.121079

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors:  David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

2.  A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells.

Authors:  N Mochizuki; S Shimizu; T Nagasawa; H Tanaka; M Taniwaki; J Yokota; K Morishita
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

3.  EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations.

Authors:  Vincent-Philippe Lavallée; Patrick Gendron; Sébastien Lemieux; Giovanni D'Angelo; Josée Hébert; Guy Sauvageau
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

4.  High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.

Authors:  Stefan Gröschel; Sanne Lugthart; Richard F Schlenk; Peter J M Valk; Karina Eiwen; Chantal Goudswaard; Wim J L van Putten; Sabine Kayser; Leo F Verdonck; Michael Lübbert; Gert-Jan Ossenkoppele; Ulrich Germing; Ingo Schmidt-Wolf; Brigitte Schlegelberger; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Bob Löwenberg; Konstanze Döhner; Ruud Delwel
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

5.  Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.

Authors:  Sanne Lugthart; Stefan Gröschel; H Berna Beverloo; Sabine Kayser; Peter J M Valk; Shama Lydia van Zelderen-Bhola; Gert Jan Ossenkoppele; Edo Vellenga; Eva van den Berg-de Ruiter; Urs Schanz; Gregor Verhoef; Peter Vandenberghe; Augustin Ferrant; Claus-Henning Köhne; Michael Pfreundschuh; Heinz A Horst; Elisabeth Koller; Marie von Lilienfeld-Toal; Martin Bentz; Arnold Ganser; Brigitte Schlegelberger; Martine Jotterand; Jürgen Krauter; Thomas Pabst; Matthias Theobald; Richard F Schlenk; Ruud Delwel; Konstanze Döhner; Bob Löwenberg; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2010-07-26       Impact factor: 44.544

Review 6.  The role of EVI1 in normal and leukemic cells.

Authors:  Silvia Buonamici; Soumen Chakraborty; Vitalyi Senyuk; Giuseppina Nucifora
Journal:  Blood Cells Mol Dis       Date:  2003 Sep-Oct       Impact factor: 3.039

7.  Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.

Authors:  Heesun J Rogers; James W Vardiman; John Anastasi; Gordana Raca; Natasha M Savage; Athena M Cherry; Daniel Arber; Erika Moore; Jennifer J D Morrissette; Adam Bagg; Yen-Chun Liu; Susan Mathew; Attilio Orazi; Pei Lin; Sa A Wang; Carlos E Bueso-Ramos; Kathryn Foucar; Robert P Hasserjian; Ramon V Tiu; Matthew Karafa; Eric D Hsi
Journal:  Haematologica       Date:  2014-01-24       Impact factor: 9.941

8.  Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor.

Authors:  K Morishita; E Parganas; T Matsugi; J N Ihle
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

9.  EVI1 Impairs myelopoiesis by deregulation of PU.1 function.

Authors:  Leopoldo Laricchia-Robbio; Kavitha Premanand; Ciro R Rinaldi; Giuseppina Nucifora
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

10.  A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.

Authors:  Hiromi Yamazaki; Mikiko Suzuki; Akihito Otsuki; Ritsuko Shimizu; Emery H Bresnick; James Douglas Engel; Masayuki Yamamoto
Journal:  Cancer Cell       Date:  2014-04-03       Impact factor: 31.743
View more
  4 in total

1.  The subtype-specific features of EVI1 and PRDM16 in acute myeloid leukemia.

Authors:  Hidemasa Matsuo; Susumu Goyama; Yasuhiko Kamikubo; Souichi Adachi
Journal:  Haematologica       Date:  2015-03       Impact factor: 9.941

2.  Imbalanced expression of polycistronic miRNA in acute myeloid leukemia.

Authors:  Ryutaro Kotaki; Hiroshi Higuchi; Daisuke Ogiya; Yasuhiro Katahira; Natsumi Kurosaki; Naoko Yukihira; Jun Ogata; Haruna Yamamoto; Syakira Mohamad Alba; Azran Azhim; Tatsuo Kitajima; Shigeaki Inoue; Kazuhiro Morishita; Koh Ono; Ryo Koyama-Nasu; Ai Kotani
Journal:  Int J Hematol       Date:  2017-08-22       Impact factor: 2.490

3.  PRDM16 isoforms differentially regulate normal and leukemic hematopoiesis and inflammatory gene signature.

Authors:  David J Corrigan; Larry L Luchsinger; Mariana Justino de Almeida; Linda J Williams; Alexandros Strikoudis; Hans-Willem Snoeck
Journal:  J Clin Invest       Date:  2018-07-23       Impact factor: 14.808

Review 4.  Multifaceted Role of PRDM Proteins in Human Cancer.

Authors:  Amelia Casamassimi; Monica Rienzo; Erika Di Zazzo; Anna Sorrentino; Donatella Fiore; Maria Chiara Proto; Bruno Moncharmont; Patrizia Gazzerro; Maurizio Bifulco; Ciro Abbondanza
Journal:  Int J Mol Sci       Date:  2020-04-10       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.